United Therapeutics Corporation (UTHR) Quick Ratio
- Quick ratio · latest quarter: Value 4.89×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 4.89× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $2.97B ÷ $607.80M ≈ 4.89× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 2.97B USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 607.80M USD | Liabilities, Current |
| Cash and equivalents | 1.80B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 859.10M USD | Marketable Securities, Current |
| Customer receivables | 310.30M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 193.80M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.97B | $607.80M | $1.80B | $859.10M | $310.30M | $193.80M | 4.89× |
| 2026-03-31 | $2.47B | $599.10M | $1.28B | $874.00M | $312.00M | $178.30M | 4.12× |
| 2025-12-31 | $3.27B | $560.60M | $1.56B | $1.36B | $350.20M | $183.10M | 5.83× |
| 2025-09-30 | $3.07B | $546.30M | $1.34B | $1.43B | $297.70M | $176.50M | 5.61× |
| 2025-06-30 | $3.43B | $527.10M | $1.59B | $1.46B | $379.30M | $169.20M | 6.50× |
| 2025-03-31 | $3.64B | $721.50M | $1.90B | $1.42B | $322.00M | $165.40M | 5.05× |
| 2024-12-31 | $3.55B | $738.10M | $1.70B | $1.57B | $279.30M | $157.90M | 4.80× |
| 2024-09-30 | $3.67B | $873.40M | $1.55B | $1.77B | $341.80M | $146.70M | 4.20× |
| 2024-06-30 | $3.26B | $832.30M | $1.36B | $1.62B | $290.70M | $136.50M | 3.92× |
| 2024-03-31 | $3.02B | $860.60M | $1.25B | $1.46B | $307.30M | $120.20M | 3.50× |
| 2023-12-31 | $3.27B | $804.40M | $1.21B | $1.79B | $278.90M | $111.80M | 4.07× |
| 2023-09-30 | $3.13B | $744.10M | $1.11B | $1.77B | $258.60M | $104.30M | 4.21× |
| 2023-06-30 | $2.95B | $370.30M | $1.07B | $1.61B | $272.70M | $103.30M | 7.97× |
| 2023-03-31 | $3.00B | $324.60M | $1.16B | $1.70B | $134.50M | $102.50M | 9.24× |
| 2022-12-31 | $3.06B | $343.20M | $961.20M | $1.88B | $220.40M | $102.00M | 8.91× |
| 2022-09-30 | $2.85B | $315.90M | $966.80M | $1.65B | $231.70M | $91.00M | 9.01× |
| 2022-06-30 | $2.43B | $331.50M | $795.20M | $1.46B | $173.40M | $89.90M | 7.33× |
| 2022-03-31 | $2.44B | $292.60M | $813.30M | $1.45B | $170.50M | $88.20M | 8.33× |
| 2021-12-31 | $2.13B | $305.40M | $894.80M | $1.04B | $198.70M | $93.80M | 6.97× |
| 2021-09-30 | $2.21B | $320.00M | $908.50M | $1.09B | $212.80M | $96.70M | 6.92× |
| 2021-06-30 | $2.14B | $311.40M | $942.20M | $1.03B | $173.40M | $89.90M | 6.88× |
| 2021-03-31 | $1.87B | $302.40M | $832.30M | $899.00M | $141.10M | $92.20M | 6.19× |
| 2020-12-31 | $1.99B | $323.30M | $738.70M | $1.10B | $157.40M | $86.50M | 6.16× |
| 2020-09-30 | $1.73B | $258.90M | $670.20M | $910.30M | $152.30M | $87.90M | 6.69× |
| 2020-06-30 | $1.73B | $255.00M | $685.40M | $875.30M | $172.00M | $89.70M | 6.79× |
| 2020-03-31 | $1.69B | $207.30M | $875.20M | $669.30M | $149.60M | $92.00M | 8.17× |
| 2019-12-31 | $1.64B | $463.00M | $738.40M | $747.50M | $151.40M | $93.40M | 3.54× |
| 2019-09-30 | $1.75B | $469.90M | $719.70M | $850.30M | $183.60M | $94.10M | 3.73× |
| 2019-06-30 | $1.97B | $463.50M | $881.30M | $904.90M | $181.00M | $96.90M | 4.24× |
| 2019-03-31 | $1.76B | $270.00M | $790.60M | $814.50M | $159.80M | $96.20M | 6.54× |
| 2018-12-31 | $1.59B | $276.60M | $669.20M | $746.70M | $175.70M | $101.00M | 5.75× |
| 2018-09-30 | $1.45B | $372.40M | $656.00M | $581.60M | $215.20M | $101.00M | 3.90× |
| 2018-06-30 | $1.46B | $350.00M | $745.90M | $467.10M | $251.30M | $102.70M | 4.18× |
| 2018-03-31 | $1.47B | $318.40M | $932.70M | $324.10M | $211.10M | $101.50M | 4.61× |
| 2017-12-31 | $1.22B | $444.70M | $705.10M | $222.30M | $297.10M | $107.90M | 2.75× |
| 2017-09-30 | $1.46B | $789.40M | $1.07B | $143.20M | $251.80M | $114.40M | 1.85× |
| 2017-06-30 | $1.39B | $838.80M | $1.01B | $109.30M | $273.90M | $114.10M | 1.66× |
| 2017-03-31 | $1.34B | $427.70M | $1.12B | $33.70M | $188.00M | $106.90M | 3.14× |
| 2016-12-31 | (m) | $332.50M | $1.02B | (m) | $214.50M | $100.00M | (m) |
| 2016-09-30 | (m) | $314.60M | $953.00M | (m) | $224.60M | $92.40M | (m) |
| 2016-06-30 | (m) | $292.40M | $837.50M | (m) | $238.10M | $89.10M | (m) |
| 2016-03-31 | (m) | $357.10M | $846.80M | (m) | $194.80M | $87.60M | (m) |
| 2015-12-31 | (m) | $440.82M | $831.80M | (m) | $192.83M | $81.33M | (m) |
| 2015-09-30 | (m) | $557.34M | $765.21M | (m) | $179.64M | $80.84M | (m) |
| 2015-06-30 | (m) | $542.41M | $254.36M | (m) | $169.21M | $77.25M | (m) |
| 2015-03-31 | (m) | $646.75M | $426.51M | (m) | $156.15M | $72.47M | (m) |
| 2014-12-31 | (m) | $504.31M | $397.70M | (m) | $162.29M | $66.93M | (m) |
| 2014-09-30 | (m) | $760.65M | $497.29M | (m) | $139.90M | $63.67M | (m) |
| 2014-06-30 | (m) | $659.07M | $259.05M | (m) | $212.90M | $58.03M | (m) |
| 2014-03-31 | (m) | $658.53M | $413.79M | (m) | $131.77M | $51.72M | (m) |
| 2013-12-31 | (m) | $687.67M | $278.89M | (m) | $126.30M | $47.76M | (m) |
| 2013-09-30 | (m) | $468.91M | $322.23M | (m) | $130.64M | $49.62M | (m) |
| 2013-06-30 | (m) | $412.23M | $343.55M | (m) | $131.56M | $44.71M | (m) |
| 2013-03-31 | (m) | $176.60M | $262.13M | (m) | $101.35M | $39.74M | (m) |
| 2012-12-31 | (m) | $176.75M | $154.03M | (m) | $116.63M | $37.25M | (m) |
| 2012-09-30 | (m) | $227.62M | $263.43M | (m) | $108.95M | $46.85M | (m) |
| 2012-06-30 | (m) | $187.66M | $157.01M | (m) | $98.58M | $46.63M | (m) |
| 2012-03-31 | (m) | $175.54M | $156.67M | (m) | $89.15M | $45.76M | (m) |
| 2011-12-31 | (m) | $212.58M | $162.68M | (m) | $88.68M | $45.98M | (m) |
| 2011-09-30 | (m) | $424.95M | $343.98M | (m) | $87.39M | $45.80M | (m) |
| 2011-06-30 | (m) | $453.54M | $321.12M | (m) | $82.53M | $41.26M | (m) |
| 2011-03-31 | (m) | $441.95M | $288.96M | (m) | $65.42M | $38.08M | (m) |
| 2010-12-31 | (m) | $428.69M | $252.16M | (m) | $73.71M | $35.52M | (m) |
| 2010-09-30 | (m) | $397.46M | $210.19M | (m) | $75.57M | $33.42M | (m) |
| 2010-06-30 | (m) | $365.72M | $285.41M | (m) | $83.51M | $30.24M | (m) |
| 2010-03-31 | (m) | (m) | $189.96M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $330.19M | $100.35M | (m) | $50.63M | $26.36M | (m) |
| 2009-09-30 | (m) | (m) | $134.50M | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | $133.52M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $129.45M | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | $139.32M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |